| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC
|
Camidge, D. Ross
|
|
|
3 |
1 |
p.
|
artikel
|
| 2 |
Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005)
|
Lee, Jiyun
|
|
|
3 |
1 |
p.
|
artikel
|
| 3 |
EGFR-Mutated Lung Adenocarcinoma Successfully Treated With Osimertinib After Spontaneous Transformation to SCLC and Adenocarcinoma With Neuroendocrine Differentiation: Case Report
|
Takuma, Sho
|
|
|
3 |
1 |
p.
|
artikel
|
| 4 |
Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report
|
Crowley, Fionnuala
|
|
|
3 |
1 |
p.
|
artikel
|
| 5 |
Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case Report
|
Endo, Yoshinari
|
|
|
3 |
1 |
p.
|
artikel
|
| 6 |
Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations
|
Arbour, Kathryn C.
|
|
|
3 |
1 |
p.
|
artikel
|
| 7 |
Phase 3 Trial of BI 695502 Plus Chemotherapy Versus Bevacizumab Reference Product Plus Chemotherapy in Patients With Advanced Nonsquamous NSCLC
|
Kim, Edward S.
|
|
|
3 |
1 |
p.
|
artikel
|
| 8 |
Prognostic Value of Clinical Staging According to TNM in Patients With SCLC: A Real-World Surveillance Epidemiology and End-Results Database Analysis
|
Arriola, Edurne
|
|
|
3 |
1 |
p.
|
artikel
|
| 9 |
Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study
|
Yang, Xue-Ning
|
|
|
3 |
1 |
p.
|
artikel
|
Tijdschrift beschrijving